RE:No questions on cancer I think there are interesting questions to ask based on the AACR data, even the first patients interaction with the media raises questions. I'd want to know how melanoma might fit into the program given it's not include in the Ph1 atm.
Maybe the Q&A issue was technical.
SPCEO1 wrote: Perhaps the most remarkable thing is that the AACR data created zero excitement in the analyst community. How is that possible? You have an exciting cancer drug that just got fast tracked in the pre-clinical stage and has pretty fascinating data and no analyst wants to ask a question about that??? Hard to fathom.